Milan

• A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting
  2023-504022-19-01 5 2024-12-13 Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
• A trial to learn if AZD5492 is safe and works alone and in combination with other cancer treatments in adults with B-cell blood cancers. Recruiting
  2024-511099-34-00 1 2024-12-12 B-Cell Malignancies
• A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting
  2022-500455-23-00 5 2024-12-11 Candidemia
• A Phase 1/2 Study of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 Recruiting
  2023-506028-10-00 7 2024-12-11 Myotonic Dystrophy
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k … Recruiting
  2023-510150-17-00 4 2024-12-11 Active, refractory systemic lupus erythematosus (SLE), and active, re
• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 4 2024-12-10 Diffuse cutaneous systemic sclerosis (dcSSc)
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subject … Recruiting
  2024-513860-25-00 9 2024-12-10 Ovarian Neoplasms
• Abatacept for therapy of IgG4-related disease Recruiting
  2024-512863-30-00 4 2024-12-09 IgG4-related disease
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• Conservative vs conventional oxygen administration in critically ill patients: effects on ICU mortality. A multicentre randomized open label … Recruiting
  2024-518092-62-00 5 2024-12-09 Adult critically ill patients requiring non-invasive (NIMV) or invasiv
• A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therap … Recruiting
  2024-512053-24-00 4 2024-12-05 recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSC
• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• ​Clinical trial of patritumab deruxtecan in people with gastrointestinal cancers​ Recruiting
  2024-512442-41-00 9 2024-12-03 Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinom
• A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting
  2024-514177-21-00 4 2024-12-02 Solid tumours
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in … Recruiting
  2023-508949-40-00 4 2024-11-29 Eosinophilic esophagitis
• An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa … Recruiting
  2024-517820-21-00 4 2024-11-29 cystic fibrosis associated to persistent Staphylococcus aureus (includ
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting
  2024-513441-36-00 4 2024-11-27 MMRp/ MSS colon cancer
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensate … Recruiting
  2024-512895-36-00 5 2024-11-25 Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Metronomic neoadjuvant capecitabine and cyclophosphamide in huge (PCI>28) Pseudomyxoma peritonei (PMP) patients candidates to cytoreductive … Recruiting
  2024-514329-42-00 4 2024-11-22 Pseudomyxoma peritonei patients with high tumor burden.
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease

Showing 841–864 of 2,361 trials